SciELO - Scientific Electronic Library Online

vol.33 número2Colistín en la era post-antibiótica índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados




Links relacionados

  • En proceso de indezaciónCitado por Google
  • No hay articulos similaresSimilares en SciELO
  • En proceso de indezaciónSimilares en Google


Revista chilena de infectología

versión impresa ISSN 0716-1018


BERNAL-VARGAS, Mónica A  y  CORTES, Jorge A. Duration of treatment and oral administrad on of antibiotics in community acquired pneumonia. Rev. chil. infectol. [online]. 2016, vol.33, n.2, pp.177-186. ISSN 0716-1018.

Community acquired pneumonia (CAP) is an important cause of morbidity and mortality around the world, with high treatment costs due to hospitalization and complications (adverse events due to medications, antibiotic resistance, healthcare associated infections, etc.). It has been proposed administration of short courses and early switch of intravenous administration to oral therapy to avoid costs and complications. There are recommendations about these topics in national and intemational guidelines, based on clinical trials which do not demónstrate diffe-rences in mortality and complications when there is an early change from intravenous administration to the oral route. There are no statistically significant differences in safety and resolution of the disease when short and long treatment schemes were compared. In this review we present the most important guidelines and clinical studies, taking into account the pharmacological differences between different medications. It is considered that early switch from intravenous to oral administration route and use of short cycles in CAP is safe and brings benefits to patients and institutions.

Palabras clave : Pneumonia; pneumonia/therapy; anti-bacterial agents; adult; therapy; drug administration routes; administration and dosage.

        · resumen en Español     · texto en Español     · Español ( pdf )


Creative Commons License Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons